<?xml version="1.0" encoding="UTF-8"?>
<p>ZIKV vaccine development has been very challenging due to existing cross-reactive anti-DENV antibodies that augment viral infections [
 <xref rid="B11-viruses-12-01041" ref-type="bibr">11</xref>]. There are multiple ZIKV candidate vaccines under development with several of them in phase 2 clinical trials [
 <xref rid="B12-viruses-12-01041" ref-type="bibr">12</xref>,
 <xref rid="B13-viruses-12-01041" ref-type="bibr">13</xref>,
 <xref rid="B14-viruses-12-01041" ref-type="bibr">14</xref>]. There have also been efforts for developing effective therapies against ZIKV [
 <xref rid="B15-viruses-12-01041" ref-type="bibr">15</xref>], and a number of antivirals have been identified in vitro, but their safety and efficacy in vivo remain to be determined and none have been licensed for the treatment of ZIKV infection [
 <xref rid="B9-viruses-12-01041" ref-type="bibr">9</xref>].
</p>
